Literature DB >> 19002564

The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.

Orsolya Polgar1, John F Deeken, Lilangi S Ediriwickrema, Akina Tamaki, Seth M Steinberg, Robert W Robey, Susan E Bates.   

Abstract

ABCG2 is a half-transporter initially described in multidrug-resistant cancer cells and lately identified as an important factor in the pharmacokinetics of its substrates. Q141K is by far the most intensively studied single nucleotide polymorphism of ABCG2 with potential clinical relevance. Here we used stably transfected HEK cells to study the Q141K polymorphism together with the deletion of amino acids 315-316, which were recently reported to coexist in two cancer cell lines (A549 and SK-OV-3). Functional studies confirmed our previous report that when normalized to surface expression, Q141K has impaired transport of mitoxantrone. This result was extended to include the ABCG2-specific substrate pheophorbide a. While we found no functional consequence of deleting amino acids 315 and 316, we did find that the deletion mutant is no longer recognized by the BXP-21 antibody. We conclude that amino acids 315 and 316 form part of the epitope for the BXP-21 antibody.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002564      PMCID: PMC2631614          DOI: 10.1007/s11010-008-9940-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  34 in total

1.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

Authors:  Shinji Mizuarai; Naohiko Aozasa; Hidehito Kotani
Journal:  Int J Cancer       Date:  2004-03-20       Impact factor: 7.396

2.  Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.

Authors:  Csilla Ozvegy; András Váradi; Balázs Sarkadi
Journal:  J Biol Chem       Date:  2002-10-08       Impact factor: 5.157

3.  Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).

Authors:  Yasumasa Honjo; Kuniaki Morisaki; Lyn Mickley Huff; Robert W Robey; Jeffrey Hung; Michael Dean; Susan E Bates
Journal:  Cancer Biol Ther       Date:  2002 Nov-Dec       Impact factor: 4.742

4.  Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.

Authors:  Thomas Litman; Ulla Jensen; Alastair Hansen; Kuang-Ming Covitz; Zhirong Zhan; Patricia Fetsch; Andrea Abati; Paul Robert Hansen; Thomas Horn; Torben Skovsgaard; Susan E Bates
Journal:  Biochim Biophys Acta       Date:  2002-09-20

5.  Pheophorbide a is a specific probe for ABCG2 function and inhibition.

Authors:  Robert W Robey; Kenneth Steadman; Orsolya Polgar; Kuniaki Morisaki; Margaret Blayney; Prakash Mistry; Susan E Bates
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

6.  Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.

Authors:  Miyu Miwa; Satomi Tsukahara; Etsuko Ishikawa; Sakiyo Asada; Yasuo Imai; Yoshikazu Sugimoto
Journal:  Int J Cancer       Date:  2003-12-10       Impact factor: 7.396

7.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

Authors:  Zhe-Sheng Chen; Robert W Robey; Martin G Belinsky; Irina Shchaveleva; Xiao-Qin Ren; Yoshikazu Sugimoto; Douglas D Ross; Susan E Bates; Gary D Kruh
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

8.  Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.

Authors:  Alex Sparreboom; Hans Gelderblom; Sharon Marsh; Ranjeet Ahluwalia; Rosendo Obach; Paola Principe; Chris Twelves; Jaap Verweij; Howard L McLeod
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

9.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

Authors:  Csilla Ozvegy-Laczka; Tamás Hegedus; György Várady; Olga Ujhelly; John D Schuetz; András Váradi; György Kéri; László Orfi; Katalin Német; Balázs Sarkadi
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

10.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.

Authors:  R W Robey; Y Honjo; K Morisaki; T A Nadjem; S Runge; M Risbood; M S Poruchynsky; S E Bates
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  1 in total

Review 1.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.